Please use this identifier to cite or link to this item:
https://hdl.handle.net/1959.11/56295
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jadhav, Satyawan B | en |
dc.contributor.author | Crass, Ryan L | en |
dc.contributor.author | Chapel, Sunny | en |
dc.contributor.author | Kerschnitzki, Michael | en |
dc.contributor.author | Sasiela, William J | en |
dc.contributor.author | Emery, Maurice G | en |
dc.contributor.author | Amore, Benny M | en |
dc.contributor.author | Barrett, P Hugh R | en |
dc.contributor.author | Watts, Gerald F | en |
dc.contributor.author | Catapano, Alberico L | en |
dc.date.accessioned | 2023-10-06T04:07:19Z | - |
dc.date.available | 2023-10-06T04:07:19Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.citation | European Heart Journal- Cardiovascular Pharmacotherapy, 8(6), p. 578-586 | en |
dc.identifier.issn | 2055-6845 | en |
dc.identifier.issn | 2055-6837 | en |
dc.identifier.uri | https://hdl.handle.net/1959.11/56295 | - |
dc.description.abstract | <p><b>Aims</b> Many patients are unable to achieve guideline-recommended LDL cholesterol (LDL-C) targets, despite taking maximally tolerated lipid-lowering therapy. Bempedoic acid, a competitive inhibitor of ATP citrate lyase, significantly lowers LDL-C with or without background statin therapy in diverse populations. Because pharmacodynamic interaction between statins and bempedoic acid is complex, a dose-response model was developed to predict LDL-C pharmacodynamics following administration of statins combined with bempedoic acid.</p> <p><b>Methods And Results</b> Bempedoic acid and statin dosing and LDL-C data were pooled from 14 phase 1-3 clinical studies. Dose-response models were developed for bempedoic acid monotherapy and bempedoic acid-statin combinations using previously published statin parameters. Simulations were performed using these models to predict change in LDL-C levels following treatment with bempedoic acid combined with clinically relevant doses of atorvastatin, rosuvastatin, simvastatin, and pravastatin. Dose-response models predicted that combining bempedoic acid with the lowest statin dose of commonly used statins would achieve a similar degree of LDL-C lowering as quadrupling that statin dose" for example, the predicted LDL-C lowering was 54% with atorvastatin 80 mg compared with 54% with atorvastatin 20 mg + bempedoic acid 180 mg, and 42% with simvastatin 40 mg compared with 46% with simvastatin 10 mg + bempedoic acid 180 mg.</p> <p><b>Conclusion</b> These findings suggest bempedoic acid combined with lower statin doses offers similar LDL-C lowering compared with statin monotherapy at higher doses, potentially sparing patients requiring additional lipid-lowering therapies from the adverse events associated with higher statin doses.</p> | en |
dc.language | en | en |
dc.publisher | Oxford University Press | en |
dc.relation.ispartof | European Heart Journal- Cardiovascular Pharmacotherapy | en |
dc.rights | Attribution-NonCommercial 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.title | Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model | en |
dc.type | Journal Article | en |
dc.identifier.doi | 10.1093/ehjcvp/pvab064 | en |
dcterms.accessRights | UNE Green | en |
local.contributor.firstname | Satyawan B | en |
local.contributor.firstname | Ryan L | en |
local.contributor.firstname | Sunny | en |
local.contributor.firstname | Michael | en |
local.contributor.firstname | William J | en |
local.contributor.firstname | Maurice G | en |
local.contributor.firstname | Benny M | en |
local.contributor.firstname | P Hugh R | en |
local.contributor.firstname | Gerald F | en |
local.contributor.firstname | Alberico L | en |
local.profile.school | Faculty of Medicine and Health | en |
local.profile.email | pbarret6@une.edu.au | en |
local.output.category | C1 | en |
local.record.place | au | en |
local.record.institution | University of New England | en |
local.publisher.place | The United Kingdom | en |
local.format.startpage | 578 | en |
local.format.endpage | 586 | en |
local.peerreviewed | Yes | en |
local.identifier.volume | 8 | en |
local.identifier.issue | 6 | en |
local.title.subtitle | predictions from a dose–response model | en |
local.access.fulltext | Yes | en |
local.contributor.lastname | Jadhav | en |
local.contributor.lastname | Crass | en |
local.contributor.lastname | Chapel | en |
local.contributor.lastname | Kerschnitzki | en |
local.contributor.lastname | Sasiela | en |
local.contributor.lastname | Emery | en |
local.contributor.lastname | Amore | en |
local.contributor.lastname | Barrett | en |
local.contributor.lastname | Watts | en |
local.contributor.lastname | Catapano | en |
dc.identifier.staff | une-id:pbarret6 | en |
local.profile.orcid | 0000-0003-3223-6125 | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.identifier.unepublicationid | une:1959.11/56295 | en |
local.date.onlineversion | 2021-08-27 | - |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
local.title.maintitle | Pharmacodynamic effect of bempedoic acid and statin combinations | en |
local.relation.fundingsourcenote | Esperion Therapeutics, Inc | en |
local.output.categorydescription | C1 Refereed Article in a Scholarly Journal | en |
local.search.author | Jadhav, Satyawan B | en |
local.search.author | Crass, Ryan L | en |
local.search.author | Chapel, Sunny | en |
local.search.author | Kerschnitzki, Michael | en |
local.search.author | Sasiela, William J | en |
local.search.author | Emery, Maurice G | en |
local.search.author | Amore, Benny M | en |
local.search.author | Barrett, P Hugh R | en |
local.search.author | Watts, Gerald F | en |
local.search.author | Catapano, Alberico L | en |
local.open.fileurl | https://rune.une.edu.au/web/retrieve/ca911cbc-00de-4d69-9e51-d09ae8118c9b | en |
local.uneassociation | Yes | en |
local.atsiresearch | No | en |
local.sensitive.cultural | No | en |
local.year.available | 2021 | - |
local.year.published | 2022 | - |
local.fileurl.open | https://rune.une.edu.au/web/retrieve/ca911cbc-00de-4d69-9e51-d09ae8118c9b | en |
local.fileurl.openpublished | https://rune.une.edu.au/web/retrieve/ca911cbc-00de-4d69-9e51-d09ae8118c9b | en |
local.subject.for2020 | 320101 Cardiology (incl. cardiovascular diseases) | en |
local.subject.seo2020 | 200105 Treatment of human diseases and conditions | en |
local.profile.affiliationtype | External Affiliation | en |
local.profile.affiliationtype | External Affiliation | en |
local.profile.affiliationtype | External Affiliation | en |
local.profile.affiliationtype | External Affiliation | en |
local.profile.affiliationtype | External Affiliation | en |
local.profile.affiliationtype | External Affiliation | en |
local.profile.affiliationtype | External Affiliation | en |
local.profile.affiliationtype | UNE Affiliation | en |
local.profile.affiliationtype | External Affiliation | en |
local.profile.affiliationtype | External Affiliation | en |
Appears in Collections: | Journal Article School of Health |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
openpublished/PharmacodynamicBarret2022JournalArticle.pdf | Published Version | 674.81 kB | Adobe PDF Download Adobe | View/Open |
SCOPUSTM
Citations
14
checked on Sep 28, 2024
This item is licensed under a Creative Commons License